Hypoglycaemia with oral antidiabetic drugs: Results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide

Drug Safety

Volumn 32, Issue 5, 2009, Pages 409-418

  Vlckova, Veronika ^a,c,d   Cornelius, Victoria ^a,b   Kasliwal, Rachna ^a,b   Wilton, Lynda ^a,b   Shakir, Saad A W ^a,b  

^a DRUG SAFETY RESEARCH UNIT   (United Kingdom)

^b UNIVERSITY OF PORTSMOUTH   (United Kingdom)

^c Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^d CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

NATEGLINIDE; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HAZARD ASSESSMENT; HUMAN; HYPOGLYCEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; CARBAMATES; COHORT STUDIES; CYCLOHEXANES; DIABETES MELLITUS, TYPE 2; DRUG MONITORING; DRUG PRESCRIPTIONS; FEMALE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INCIDENCE; MALE; MIDDLE AGED; PHENYLALANINE; PIPERIDINES; SEX FACTORS; THIAZOLIDINEDIONES;

EID: 65949118062     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200932050-00004     Document Type: Article

References (39)

1. WHO Department of Noncommunicable Disease Surveillance. Definition, diagnosis and classification of diabetes mellitus and its complications [online]. Available from URL: http://www.staff.ncl.ac.uk/philip.home/who-dmc. htm#DefinDiag [Accessed 2008 Apr 28]
2. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004 May; 27 (5): 1047-53
3. Virally M, Blickle JF, Girard J, et al. Type 2 diabetes mellitus: epidemiology, pathophysiology, unmet needs and therapeutical perspectives. Diabetes Metab 2007 Sep; 33 (4): 231-44
4. Hussein Z, Wentworth JM, Nankervis AJ, et al. Effectiveness and side effects of thiazolidinediones for type 2 diabetes: real-life experience from a tertiary hospital. Med J Aust 2004 Nov 15; 181 (10): 536-9
5. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999 Jun 2; 281 (21): 2005-12
6. Leese GP, Wang J, Broomhall J, et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care 2003 Apr; 26 (4): 1176-80
7. Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia 2002 Jul; 45 (7): 937-48
8. Saleh M, Grunberger G. Hypoglycemia: an excuse for poor glycemic control? Clin Diabetes 2001 Oct; 19 (4): 161-7
9. Kasliwal R, Wilton L, Shakir SAW. Monitoring the safety of pioglitazone: results of a prescription-event monitoring study of 12,772 patients in England. Drug Saf 2008; 31 (10): 839-50
10. Twaites B, Wilton LV, Layton D, et al. Safety of nateglinide as used in general practice in England: results of a prescription-event monitoring study. Acta Diabetol 2007 Dec; 44 (4): 233-9
11. Marshall V, Wilton L, Shakir S. Safety profile of repaglinide as used in general practice in England: results of a prescription-event monitoring study. Acta Diabetol 2006 May; 43 (1): 6-13
12. Summary of product characteristics for Avandia (rosiglitazone maleate), Middlesex: GlaxoSmithKline UK, 2008 Mar [online]. Available from URL: http://emc.medicines.org.uk/medicine/3200/SPC/Avandia+4mg+%26+8mg+film- coated+Tablets/#UNDESIRABLE-EFFECTS [Accessed 2009 Apr 15]
13. Summary of product characteristics for Actos (pioglitazone hydrochloride), Buckinghamshire: Takeda UK Limited, 2007 Sep [online]. Available from URL: http://emc.medicines.org.uk/medicine/4236/SPC/Actos+Tablets/ #UNDESIRABLE-EFFECTS [Accessed 2009 Apr 15]
14. Nolan JJ, Jones NP, Patwardhan R, et al. Rosiglitazone taken once daily provides effective glycaemic control in patients with type 2 diabetes mellitus. Diabet Med 2000 Apr; 17 (4): 287-94
15. Aronoff S, Rosenblatt S, Braithwaite S, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 2000 Nov; 23 (11): 1605-11
16. Rosenstock J, Einhorn D, Hershon K, et al. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract 2002 May; 56 (4): 251-7
17. Stewart MW, Cirkel DT, Furuseth K, et al. Effect of metformin plus roziglitazone compared with metformin alone on glycaemic control in well-controlled type 2 diabetes. Diabet Med 2006 Oct; 23 (10): 1069-78
18. Wolffenbuttel BH, Gomis R, Squatrito S, et al. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabet Med 2000 Jan; 17 (1): 40-7
19. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002 Jan 16; 287 (3): 360-72
20. Moses RG, Gomis R, Frandsen KB, et al. Flexible mealrelated dosing with repaglinide facilitates glycemic control in therapy-naive type 2 diabetes. Diabetes Care 2001 Jan; 24 (1): 11-5
21. Saloranta C, Hershon K, Ball M, et al. Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia. J Clin Endocrinol Metab 2002 Sep; 87 (9): 4171-6
22. Shakir SAW. PEM in the UK. In: Mann RD, Andrews EB, editors. Pharmacovigilance. 2nd ed. Chichester: John Wiley & Sons Ltd, 2007: 307-16
23. St John Sutton M, Rendell M, Dandona P, et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 2002 Nov; 25 (11): 2058-64
24. TanM, Johns D, Gonzalez GG, et al. Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: a multicenter, randomized, double-blind, parallel-group trial. Clin Ther 2004 May; 26 (5): 680-93
25. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006 Dec 7; 355 (23): 2427-43
26. Derosa G, Gaddi AV, Piccinni MN, et al. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial. Diabetes Obes Metab 2006 Mar; 8 (2): 197-205
27. Kipnes MS, Krosnick A, Rendell MS, et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med 2001 Jul; 111 (1): 10-7
28. Vongthavaravat V, Wajchenberg BL, Waitman JN, et al. An international study of the effects of rosiglitazone plus sulphonylurea in patients with type 2 diabetes. Curr Med Res Opin 2002; 18 (8): 456-61
29. Mattoo V, Eckland D, Widel M, et al. Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study. Clin Ther 2005 May; 27 (5): 554-67
30. Jovanovic L, Hassman DR, Gooch B, et al. Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone. Diabetes Res Clin Pract 2004 Feb; 63 (2): 127-34
31. Raskin P, McGill J, Saad MF, et al. Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone. Diabet Med 2004 Apr; 21 (4): 329-35
32. Raskin P, Klaff L, McGill J, et al. Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin. Diabetes Care 2003 Jul; 26 (7): 2063-8
33. Rosenstock J, Hassman DR, Madder RD, et al. Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care 2004 Jun; 27 (6): 1265-70
34. Kalbag JB, Walter YH, Nedelman JR, et al. Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo. Diabetes Care 2001 Jan; 24 (1): 73-7
35. Jovanovic L, Dailey III G, Huang WC, et al. Repaglinide in type 2 diabetes: a 24-week, fixed-dose efficacy and safety study. J Clin Pharmacol 2000 Jan; 40 (1): 49-57
36. Rosenstock J, Shen SG, Gatlin MR, et al. Combination therapy with nateglinide and a thiazolidinedione improves glycemic control in type 2 diabetes. Diabetes Care 2002 Sep; 25 (9): 1529-33
37. Patel J, Anderson RJ, Rappaport EB. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study. Diabetes Obes Metab 1999 May; 1 (3): 165-72
38. Bezie Y, Molina M, Hernandez N, et al. Therapeutic compliance: a prospective analysis of various factors involved in the adherence rate in type 2 diabetes. Diabetes Metab 2006 Dec; 32 (6): 611-6
39. Rozenfeld Y, Hunt JS, Plauschinat C, et al. Oral antidiabetic medication adherence and glycemic control in managed care. Am J Manag Care 2008 Feb; 14 (2): 71-5